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Abstract 
Background. Syringomyelia and Chiari Syndrome are classified as rare diseases, but 
current known occurrence in Europe is missing. The increased ability to diagnose these 
pathologies by magnetic resonance imaging and its widespread availability has led to an 
increase of reported cases, often asymptomatic, with the need to standardize definitions, 
diagnostic criteria and treatments. 
Aims. We present shared Interregional Recommendations developed with the primary 
aim to estimate Syringomyelia and Chiari Syndrome prevalence and incidence in North 
Western Italy, with special reference to symptomatic forms.
Methods. An agreement for the standardization of definitions, classifications, diagnostic 
criteria and surgical Recommendations was reached by the multidisciplinary Interregion-
al Piemonte and Valle d’Aosta Chiari-Syringomyelia Consortium (Delphi method); next, 
in 2011 a census for Syringomyelia and Chiari Malformation was performed through the 
Interregional Piemonte and Valle d’Aosta Rare Disease Registry, integrated by a dedi-
cated form in order to estimate prevalence and  incidence. 
Results. 436 patients, 292 females, met shared interregional diagnostic criteria. Syringo-
myelia prevalence was estimated in 4.84:100 000; Chiari Malformation prevalence was 
7.74:100 000; incidence was 0.82:100 000 and 3.08:100 000 respectively. Demographics, 
neuroradiological parameters and aetiology were reported (in symptomatic and asymp-
tomatic forms). Finally, symptoms and signs, familiar and natural history were analyzed.
Conclusions. First Italian epidemiological data (prevalence, incidence) on Chiari and 
syringomyelia was collected, according to shared diagnostic Recommendations. Future 
perspectives include the adoption of these Recommendations at national level to stan-
dardize the access to diagnosis and care process and promote multicenter clinical trials.
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INTRODUCTION 
Syringomyelia (Syr) is morphologically defined at 
magnetic resonance imaging (MRI) as the presence of 
single or multiple fluid-filled cavity (syrinx) within the 
parenchyma of the spinal cord and/or the bulb (Syringo-
bulbia) and classified as a rare disease (ORPHA3280). 
About 50% of Syr patients have severe neurological dam-
age, chronic-progressive disability with complete loss 
of independence. Prognostically speaking, even more 
unfavourable is the presence of Syringobulbia (swal-
lowing and breathing bulbar centers involved). Before 
1968, neurologists diagnosed Syr only by typical neu-
rological symptoms. Since the introduction of CT my-
elography and MRI techniques for spinal cord imaging, 
the diagnosis has become easier, and many cases have 
been reported. In studies conducted before the advent 
of modern neuroimaging, prevalence ranged from 3.3 to 
8.5/100 000 [1-3]; after the advent of MRI estimated 
prevalence ranged from 1.9 to 8.4/100 000 [4, 5]. 
Chiari Malformation (CM) includes a heterogeneous 
group of abnormalities characterized by the caudal cer-
ebellum ptosis through the foramen magnum; clinical 
manifestations define the Arnold-Chiari or Chiari Syn-
drome (CS). The malformation can cause a wide variety 
of neurological symptoms, often vague or nonspecific, 
such as headaches, ocular disturbances, otoneurologic 
disturbances, lower cranial nerve signs, cerebellar ataxia, 
or spasticity [6]. Onset of symptoms is usually in the 
third decade of life. However, many individuals with 
CM remain asymptomatic even later in life. A US study 
estimated 400 000 patients affected by Chiari type 1 
Malformation (CMI), the most common CM type. The 
epidemiology of CMI malformation has been scarcely 
investigated. The true population prevalence of CMI is 
unknown and there are no studies on CMI incidence. A 
retrospective analysis of more than 22 000 neuroimaging 
diagnoses [7] provided indirect data of CMI prevalence, 
estimable in 1:1280 (0.77%). When CM is defined by 
cerebellar tonsil position 5 mm or more below the fora-
men magnum, imaging prevalence studies estimate CM 
prevalence at between 0.24 and 3.6% of the population 
[8]; the discrepancy between these estimates is a result 
of the different age groups analysed, substantially higher 
in children and young adults compared with older adults. 
In Italy and in the European Community the CMI is 
classified as a rare disease (ORPHA268882), but cur-
rent known occurrence data in Europe is missing. 
The increased ability to diagnose CM and Syr by MRI 
and its widespread availability has led to an increase of 
reported cases, often asymptomatic or minimally symp-
tomatic, with the need to standardize definitions, diag-
nostic criteria and treatments. 
In 2001 DM 279/2001, National Law [9] set up the 
Italian National Network for rare diseases, to deal with 
the prevention, surveillance, diagnosis and treatment of 
rare diseases (RD), including Arnold-Chiari or Chiari 
Syndrome; the same law activated the RD National Reg-
istry located at the Istituto Superiore di Sanità, which is 
expected to receive epidemiological data from Regional 
Registries. A Regional Decree (2/3/2004, n. 22-11870) 
established the Piemonte Regional Network for the pre-
vention, screening, diagnosis and therapy of RD. More-
over, it obliges the Hospital Units to report RD in the 
Regional Registry [10], with epidemiological and legisla-
tive purposes (i.e. to regulate the access on exemption 
path for RD). In 2005 because of the low prevalence 
estimates, the potential clinical severity in chronically 
debilitating nature and the resulting significant expense 
for its treatment, Syr was inserted as RD involving the 
nervous system in Piemonte and Valle d’Aosta [11]. 
Now, with the adoption of the new National law on Es-
sential Assistance Levels [12], Syr is recognized also as 
RD in all Italian regions, but previously this was recog-
nized as RD only in Piemonte, Valle d’Aosta, Toscana 
and Marche; for this reason Italian epidemiological data 
on Syr was not available in the RD National Registry.
Syr and CM are classified as rare diseases on Or-
phanet, the International reference portal for RD and 
orphan drugs, but current prevalence data is missing.
Guidelines on diagnostic criteria and case definition 
are missing, and consequently estimation of the preva-
lence in Piemonte and Valle d’Aosta for symptomatic 
and asymptomatic forms are missing. 
In 2008 a consortium dedicated to the study of Syr 
and CM began its activity in the Piemonte and Valle 
D’Aosta regions, as part of the Rare Diseases Network 
of the Italian National Health Service, with the aims to 
standardize/share definitions, classifications, care and 
diagnostic approaches. 
The consortium, named the Interregional Chiari-
Syringomyelia Consortium (CSC), was composed by 
clinicians (neurologists, neurosurgeons, neuroradi-
ologists, physiatrists, neuro-urologists, psychologists, 
speech pathologists, spinal surgeons, pain specialists), 
experts of public health for RD, and patient association 
representatives [13]. In 2010 the CSC Recommenda-
tions were proposed: some of these indications derived 
from the outcomes of the CSC meetings, others were 
from the First International Chiari Consensus Confer-
ence, held in Milan in 2009 [14].
Diagnostic, Surgical and Rehabilitative Recommenda-
tions were approved by the members of Technical-Spe-
cialized Task-force supporting the Regional Center of 
Coordination for RD and by the following scientific so-
cieties: Italian Society of Neurology, Piemonte and Valle 
d’Aosta section; Italian Society of Neurologists, Neuro-
surgeons, Neuroradiologists, Piemonte-Valle d’Aosta-
Liguria section; Italian Society of Physical Medicine 
and Rehabilitation, Piemonte section [15]. The docu-
ment was published as technical-scientific integration of 
the Regional Legislation (DGR n. 95-13748, 29 March 
2010), specifying the Institution of the first Center of Ex-
pertise for Chiari and Syringomyelia in Torino [16, 17].
In this study, based on the Interregional Recommen-
dations, we present the first estimation of prevalence 
and incidence of Syr and CM in North Western Italy 
(Piemonte and Valle d’Aosta), with special reference to 
symptomatic forms (Symptomatic Syringomyelia: SS; 
Chiari Syndrome: CS).
MATERIAL AND METHODS
Interregional recommendations
In order to estimate the epidemiological indices 
(prevalence and incidence), the diagnostic criteria used 
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for case definition was based on the Interregional Diag-
nostic, Surgical and Rehabilitative Recommendations. 
The Recommendations were developed following sev-
eral steps: a) collecting all available evidence on clini-
cal studies related to Syr and CM. The following da-
tabases were queried for literature review on Syr and 
CM: Medline (PubMed interface, www.pubmed.gov)¸ 
Cochrane Library (Health Library of Piedmont, www.
bvspiemonte.it), National Guidelines Clearinghouse 
(www.guideline.gov). The literature searching strat-
egy was conducted by combining: the Medical Sub-
ject Heading (MeSH): “Arnold-Chiari Malformation” 
or “Syringomyelia” or “Arnold-Chiari Malformation” 
AND “Syringomyelia”; Publication type (PT): “System-
atic Reviews”, “Practice Guideline”, “Meta-Analysis”, 
“Randomized Controlled Trial”; b) assessing studies for 
relevance. All studies were selected and critically evalu-
ated. Results with low evidence level were restricted 
for date (last 10 years) and language (English, French, 
German, Spanish, Italian); these were also selected and 
critically evaluated; c) categorising the evidence. Each 
expert member expressed an evaluation of the articles, 
giving a score between 0 (strongly disagree) and 10 
(strongly agree), according to the Delphi method [18]. 
If there was an agreement, the document was revisited 
in textual form and submitted to the working group for 
the final approval and subsequent drafting of the ulti-
mate document; for evaluation lower or equal to 7 it 
was necessary to propose an alternative text version and 
relative notes. If no agreement was reached, the docu-
ment came back to the recommendation authors with 
comments for necessary changes and resubmitted to 
the experts involved. When an agreement was reached, 
the document in the preliminary form was prepared and 
submitted to the judgment of the entire experts group 
for final consensus. A description of the sections of the 
Recommendations including classifications, radiologi-
cal and clinical definitions, surgical and conservative 
indications are reported in Table 1 and Table 2. 
Census study
According to these Recommendations, in 2011 a 
Syr and Chiari census study was performed through 
the Interregional Piemonte and Valle d’Aosta Registry 
of RD, integrated by a dedicated Case Report Form, 
reported in Figure 1; the CSC form was developed by 
the Chiari-Syringomyelia Consortium and filled out by 
every specialist (neurologist or neurosurgeon) involved 
in the diagnosis. 
We integrate the data extracted from the RD Reg-
istry (minimal data set) with the CSC form in order 
to estimate Syr and Chiari prevalence and incidence; 
moreover, the CSC form enriched the information pro-
viding further socio-demographics and clinical data. 
The study was approved by the Local Ethic Committee 
(“Prospective collaborative epidemiologic, clinic and 
genetic study in CM with and without Syr, hereditary 
connective tissue disorders and tethered cord”, Proto-
col n. 7837, 1/2/2010, Città della Salute e della Scienza 
di Torino Hospital, Turin). All partecipants gave signed 
informed consent at the time of inclusion in the census 
study. 
Statistical analysis
Up to 31 December 2011, the Syr and Chiari age 
standardized prevalence and the incidence rate in 2011 
with 95% confidence intervals (95% CI) in Piemonte 
and Valle d’Aosta Regions was estimated. The preva-
lence (number of alive diagnoses up to 2011 year) and 
the incidence (number of new reported cases in 2011 
year) were estimated using both the Interregional 
Piemonte and Valle d’Aosta Rare Disease Registry and 
the CSC census data for symptomatic forms. The CSC 
census data was also used to analyse asymptomatic 
forms. The standardization was performed by a direct 
method using the Italian census population at 1st Janu-
ary 2011 year (respectively 4 457 335 inhabitants in 
Piemonte and 128 230 in Valle d’Aosta, 4 585 565 to-
tal population), according to ISTAT census data (2012) 
[18, 19]. Confidence intervals were calculated assum-
ing a Poisson distribution. 
Basic statistics in terms of frequencies (absolute and 
percentage values) were calculated for: socio-demo-
graphic data, age at diagnosis, age at survey, diagnostic 
delay, MRI parameters (morphology/level), diagnoses, 
associated conditions, neurological symptoms/signs, 
types of surgery.  
All statistical analyses were performed using the Sta-
ta statistical software (StataCorp. Statistical Software: 
Release 7.0. College Station, TX: Stata Corporation. 
2001).
RESULTS
Census results
Using CSC form, 436 patients (292 females and 144 
males) met shared diagnostic criteria for Syr and/or CM 
(Table 3). Demographics, MRI parameters (morphol-
ogy/level), diagnoses, associated conditions, estimated 
prevalence and incidence data were reported respec-
tively in 347 CM patients and in 217 patients affected 
by Syr. Percentage of symptomatic Chiari (CS) and 
symptomatic Syr (SS) are represented in Figure 2. In 
2011 the estimated Syr prevalence is 4.84:100 000 and 
incidence is 0.82:100 000; the estimated CM preva-
lence is 7.74:100 000, incidence 3.08:100 000 (Table 4 
and Table 5).
Description of clinical manifestations
Major neurological symptoms in CS and in SS were 
respectively: headache (48% and 28%), cervical pain 
(30% and 24%), loss of balance (30% and 18%). Major 
neurological signs in CS and in SS respectively were: 
sensory disorders (48% and 70%), motor disorders 
(32% and 60%), cranial nerves (41% and 40%), auto-
nomic bladder disorders (14% and 19%). Neuropathic 
pain, defined on the basis of a DN4 questionnaire score 
higher or equal than 4 [30], was 19% in CS and 32% in 
SS. Familiar history was positive in 5% in CS and in 2% 
in SS (familiar forms);  pregnancy was carried out by 
vaginal delivery in 67% and 55% respectively in CS and 
SS, while by caesarean delivery (general anaesthesia) in 
23% and 35%. Scoliosis was reported in 29% of all CM 
and 32% of all Syr; 43 patients (25%) presented with 
scoliosis, CM1 and Syr.
In our study females are prevalent in all groups (Table 
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3), and in particular in the CM group (68%). A slight 
prevalence of employed compared to unemployed (stu-
dent and retired person) is present in the Syr group. 
Maybe this is due to the small sample size in the pedi-
atric subgroup in Syr (≤18 yrs, students = 11%) com-
pared to CM (20%) with average age at diagnosis of 
34 yrs (lower than 36 yrs of Syr group). This may have 
a significant social impact for the high prevalence of 
symptomatic forms in Syr (62%), potentially severely 
disabling, compared with a lower percentage (40%) of 
Chiari symptomatic forms (Figure 2, Tables 4, 5). Per-
centage in the over 60 yrs subgroup (retired person) is 
similar in both groups (18% CM and 22% Syr, Table 3).
Among CM, isolated form (CMI-B) is more frequent 
Table 1
Diagnostic Recommendations for Chiari 1 Malformation and Syringomyelia (elaborated by the Interregional Chiari and Syringo-
myelia Consortium)
Chiari Malformation (CM) classification
CM is a congenital anomaly of the cerebellum associated or not with neural tube defects
1. CM I: paraxial mesoderm disorder, with abnormalities of the posterior cranial fossa (mostly small) and the consequent descent of the 
cerebellar tonsils 
CMI-A: with Syr in MRI 
CMI-B: without Syr in MRI
2. CM II: associated with myelomeningocele (prevalent in childhood), hydrocephalus, and, less frequently, hydrosyringomyelia Other types 
of intracranial defects (hypoplastic tentorium cerebelli, cranial lacunae, anomalies of the Sylvius aqueduct) may exist
3. CM III: intracranial defects associated with Chiari II Malformation (very rare and severe form)
4. CM IV: cerebellar aplasia or hypoplasia, associated with aplasia of the tentorium cerebelli [21]
Chiari Malformation: “subtypes” classification
1. Classical CMI + craniosynostosis + osteopetrosis
2. CMII + Tethered Cord Syndrome (TCS)
3. CMI + inherited disorders of connective tissue-HDCT (i.e. Ehlers-Danlos syndrome)
4. Hypertension intracranial + hydrocephalus + space occupying process 
5. Hypotension intraspinal CSF + lumbo-peritoneal shunting [22]
Chiari Malformation (neuroradiological) definition
According to IHS diagnostic criteria (the second updated edition of “International Classification of Headache Disorders”, code 7.7), cerebellar 
tonsillar herniation is defined by one of the following on craniocervical MRI:
• ≥ 5 mm caudal descent of the cerebellar tonsils
• ≥ 3 mm caudal descent of the cerebellar tonsils plus at least one of the following indicators of crowding of the subarachnoid space in 
the area of the craniocervical junction:
• compression of the CSF spaces posterior and lateral to the cerebellum
• reduced height of the supraocciput
• increased slope of the tentorium
• kinking of the medulla oblongata [23]
Chiari Syndrome definition
CS is the clinical manifestation (symptoms and signs) of CM (radiologically defined), or “symptomatic Chiari”. 
Clinical diagnostic criteria (symptoms and neurological signs) are:
1. Headache, according to IHS diagnostic criteria characterised by at least one of the following criteria:
- precipitated by cough and/or Valsalva manoeuvre
- occipital and/or sub-occipital headache
- associated with symptoms and/or signs of brainstem, cerebellar and/or cervical cord dysfunction
2. Otoneurogical symptoms and/or signs (eg, dizziness, disequilibrium, sensations of alteration in ear pressure, hypacusia or hyperacusia, 
down-beat nystagmus, oscillopsia)
3. Transient visual symptoms (spark photopsias, visual blurring, diplopia or transient visual field deficits)
4. Demonstration of clinical signs relevant to cervical cord, brainstem or lower cranial nerves or of ataxia or dysmetria
Notes: for the diagnosis of Chiari Syndrome, in addition to the typical headache (criterion 1), neurological symptoms/signs (at least two of criteria 
2-4), evidence of posterior fossa dysfunction, are mandatory [23]
Syringomyelia/Hydromyelia: classification and definition
1. Type I: with obstruction of the foramen magnum and dilation of the central spinal canal 
A) Associated with CMI
B) Associated with other obstructive lesions of the foramen magnum
2. Type II: syringomyelia without obstruction of the foramen magnum, or idiopathic
3. Type III: syringomyelia with other diseases of the spinal cord
A) Spinal cord tumours (usually intraspinal) 
B) Traumatic myelopathy 
C) Spinal arachnoiditis and pachymeningitis
D) Myelomalacia due to compression of the spinal cord (tumour, spondylosis)
4. Type IV: pure hydromyelia, developmental widening of the central canal of the spinal cord, usually associated with hydrocephalus
Notes: 1) The diagnosis of Syringomyelia-Syringobulbia is attributable by neurologists or neurosurgeons in the presence of Syrinx/Syringobulbia 
at MRI in addition to spinal/bulbar signs related to the syrinx level. The clinical criteria are mandatory; 2) Hydromyelia is an intramedullary, 
centrally located, non-enhancing, slit-like cavitation, often localized short-segment  and occurring in a non-enlarged or only slightly enlarged 
spinal cord (“idiopathic localized hydromyelia”); clinically, patients present without neurological deficits but unspecific pain syndromes; they lack 
electrophysiological alterations and  progressive signs/symptoms specifically related to the spinal cord [24].
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(58%), while CMI-A type (CMI and Syr) is just 36%, 
according to literature data reporting association ranges 
32-74%. CM type 2 (CMII) is reported in 1%; other 
associated conditions, such as retroflexed odontoid, 
hydrocephalus, Klippel-Feil, Tethered Cord Syndrome, 
are reported in 5% of the cohort. Syr type I (associated 
to CM1) is the prevalent clinical phenotype (59%), 
while isolated Syr is at 41% (18% pure hydromyelia, 
14% secondary and 9% idiopathic). Males are more 
symptomatic than females in both symptomatic groups 
(47% in CS, 64% in SS), even if the estimations on gen-
der and on measure of tonsillar herniation don’t identify 
associated risk factors in CS patients. 
Hydromyelia patients (Pure-Hydromyelia included) 
are less than a third of Syr and are mostly asymptom-
atic (82%); this result on MRI morphology confirms the 
trend of Hydromyelia in presenting a low risk of clinical 
evolution towards symptomatic forms (18%). 
Negative prognostic factors in the Syr group, with 
higher percentage (> 50%) of symptomatic patients 
(SS), are identified (Table 5). MRI syrinx distribution: 
cranial level (syringobulbia 100%, cervical 61%) in fo-
cal/single cavity; MRI syrinx extension (multilevel or 
olocorde 81%); aetiology (Secondary 77% and Primary 
74%). In CS (Table 4) positive prognostic factor (poor/
any clinical evolution) at MRI morphology (as tonsillar 
herniation length ≥5 mm/3-4 mm/<3 mm) is a tonsillar 
descent <3 mm (100% in ACM), while a descent ≥5 
mm is not a significant prognostic indicator to clinical 
evolution in CS. 
Among different clinical phenotypes: CMII is the less 
frequent and the most severe form (100% CS); CMI-A 
and other associated condition forms are symptomatic 
in approximately 60% of cases; CMI-B (isolated Chiari) 
is mostly asymptomatic with just 25% of CS (Table 4).
A high percentage of SS patients has sensory and 
motor disturbances (respectively 70% and 60%); neu-
ropathic pain is relevant in Syr (32%), much more 
frequent than in CS group (19%). Percentage of auto-
nomic disturbances (bladder dysfunction) is similar in 
both groups (19% SS vs 14% CS). Familiar forms are 
reported, confirming a role for genetic factors in the dis-
ease pathogenesis. 
DISCUSSION
This study reports diagnostic and surgical Recom-
mendations for Chiari and Syr, according to the In-
ternational Consensus Conference in Milan in 2009, 
including a panel of experts, developed by the Inter-
regional Piemonte and Valle d’Aosta Chiari and Syrin-
gomyelia Consortium [13, 14, 15]. 
Based on these diagnostic Recommendations, the 
first Italian epidemiological study for CM and Syr was 
designed to estimate prevalence and incidence in symp-
tomatic and asymptomatic forms. 
Our census study involved patients diagnosed in 
Piemonte and Valle d’Aosta hospitals, with a total 
population of 4 484 469 inhabitants, with a 99% Cau-
casian ethnic group. The prevalence estimation for Syr 
was similar to that reported in a New Zealand study [4] 
relative to prevalence in Caucasians (5.4/100 000), but 
was higher than the results of a nationwide survey in 
Japan, where prevalence was estimated in 1.9/100 000 
[5]. We reported, to our knowledge, the first incidence 
estimates for Syr and Chiari in literature at internation-
al level.
Table 2
Surgical Recommendations for Chiari 1 Malformation and Syringomyelia (elaborated by the Interregional Chiari and Syringomy-
elia Consortium)
CSC Surgical Recommendations
• CM I-B symptomatic (CS isolated): children and adults with headache (typical) + auditory/cerebellar/spinal/visual signs
• CM I-A (CM I + Syr): children and adults, symptomatic and asymptomatic, especially in the case of
1) holocord syringomyelia 
2) evolutionary trend (clinical/MRI worsening),
3) central syringe and Vaquero Index >0.5 [25] or eccentric syringe
4) syringomyelia with syringobulbia (spinal/bulbar signes)
Notes:1 In children with CMI-A surgical indications are larger, even if asymptomatic (prognostic value of early surgery: disappearance/reduction 
of syringe), while in children with CM I-B (without syringe) surgical indications are not clear in asymptomatic forms (“wait and see”, with clinical 
and neuroradiological follow-up); 2) Asymptomatic and isolated Syringomyelia: in children and in adults surgical indications are not clear; if 
symptomatic forms, no consensus for surgery; 3) Post-traumatic Syringomyelia: no indication for direct decompression at the time of initial injury; 
a strong recommendation for surgical intervention in the presence (setting) of motor neurologic deterioration; a weak recommendation against 
surgical intervention for patients developing sensory loss/pain syndrome or for asymptomatic but expanding syrinx [26, 27].
Neurosurgical strategies
• CM I-A (with syrinx) and CMI-B symptomatic 
First Line: C1 occipito-cervical decompression with dura opening and dural plastic 
In children with isolated CM, surgery can be limited to the bone decompression (delamination of the atlanto-occipital ligament), 
without duraplasty [28, 29] 
• CM 1 and hydrocephalus 
First Line: third ventriculostomy by endoscopy 
Second Line: osteo-dural decompression of the posterior fossa 
• Re-interventions
For patients developing neurological deterioration and expanding syringe (failure of first/second Line surgery)
Notes:1) Surgical efficacy is inversely proportional to the number of treatments; 2) Section of the filum terminale (in presence of “occult” tethered 
cord) is not a procedure of choice in the treatment of Chiari Syndrome; spinal cord detethering in CMI is accepted only when a real tethered cord is 
associated.
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The etiology of CM1 malformation is, at present, 
poorly understood. In some cases, CM1 may be as-
sociated with connective tissue diseases like Ehlers-
Danhlos [22]. In the remaining cases, a multifactorial 
inheritance is the most likely explanation of the disease. 
Recently, a role for genetic factors in the disease patho-
genesis has been suggested.
In CM patients, recent studies have revealed the 
presence of a small posterior fossa (PF) leading to a 
cramped cerebellum and herniation of the tonsils into 
the top of the spinal column. Based on examination of 
skull radiographs, Aydin et al. found that the posterior 
fossa was smaller and shallower in patients with CM1 
malformation than in controls; the ratio of the poste-
rior fossa with supratentorial volumes on MR images 
is smaller in CM1 patients than in controls, and those 
with smaller posterior fossa developed symptoms ear-
lier and were more likely to respond to decompressive 
surgery. Experimentally-induced small posterior fossa 
was also found to lead to tonsillar herniation. So, it 
Figure 1.  
Dedicated clinical Consortium form developed by the Interregional Chiari and Syringomyelia 
Consortium, including medical hystory, familial, radiological, clinical and diagnostic data 
 
 
 
Figure 1
Dedicated clinical Consortium form developed by the Interregional Chiari and Syringomyelia Consortium, including medical hystory, 
familial, radiological, clinical and diagnostic data.
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has been postulated that the pathogenesis of CM1 in-
volves underdevelopment of the occipital bone, perhaps 
due to abnormal development of the occipital somite 
originating from the paraxial mesoderm, resulting in 
overcrowding in the posterior fossa [31]. In some fami-
lies, the CM1-S phenotype is inherited as autosomal 
dominat trait. Genomewide linkage analyses of several 
families with CM1 identified candidate loci on chromo-
some 15q21.1-q22.3 (maximum 2-point nonparametric 
exponential lod score of 3.33 at rs744318) and on chro-
mosome 9q22.31 (maximum multipoint parametric 
lod score of 3.05 between rs1000735 and rs2895201). 
Speer et al. postulated that an underlying gene respon-
sible for CMI/Syr may have pleiotropic effects that 
influence posterior fossa volume, other skull bone ab-
normalities, the extent of cerebellar tonsil herniation, 
and the formation of Syr [32]. At present, however, the 
number and the type of genes involved in CM1 with or 
without Syr are unclear.
The indications, optimal timing, and type of surgi-
cal intervention to treat Syr associated with CM1 are 
unclear; prospective, controlled trials are lacking. Ap-
proximately 1/3 of untreated patients with Syr have 
minimal or no neurologic progression [33]. Progres-
sive motor deficits and dysesthesias tend to respond 
more favourably to surgical intervention than sensory 
deficits. Greater syrinx size may predict a beneficial 
surgical response. Surgical intervention is suggested in 
patients with progressive motor deficits and a large syr-
inx. Suboccipital decompression, to alter the CSF flow 
and pressure dynamics, is considered the most success-
ful technique [34, 35]. Williams advocate concurrent 
syringe-arachnoid shunting [36-38].
The strength of the study is that our estimations are 
based on a population based registry such as the In-
terregional Piemonte and Valle d’Aosta Rare Diseases 
Registry, integrated by the specific clinical Consortium 
form. A clear and standardized criteria for clinical inclu-
sion was adopted. 
Moreover, the dissemination of the shared recom-
mendations has led to a greater awareness in the diag-
nostic process, especially improving its appropriateness 
of symptomatic versus asymptomatic forms.
A limitation of the study is the geographical local 
60%40% 38%62%
Asymptomatic (ACM) Asymptomatic Syr (AS)
Chiari Syndrome (CS) Symptomatic Syr (SS)
Figure 2
Percentages of symptomatic/asymptomatic forms in Chiari and Syringomyelia: SS are prevalent (62%) whereas CS are only 40%.
Table 3
Summary of demographic and clinical data (gender, age, occupational status, surgery) in all patients and in CM/Syr patient groups; 
percentages in brackets
Patient Group
All CMa Syra
n = 436 n = 347 n =  217
Gender (%) M 144 (33) 111 (32) 78 (36)
F 292 (67) 236 (68) 139 (64)
Occupational status (%) Employed 192 (44) 132 (38) 111 (51)
Unemployedb 244 (56) 215 (62) 106 (49)
Age (%) Pediatric (≤18 yrs)
Adult (18-60 yrs)
Over 60 yrs
70 (16)
283 (65)
83 (19)
69 (20)
215 (62)
63 (18)
24 (11)
145 (67)
48 (22)
Surgery (%) Yes
No
113 (26)
323 (74)
107 (31)
240 (69)
67 (31)
150 (69)
a CM/Syr patient group includes associated forms: 128 patients with CMI/II+Syr; b Unemployed person, retired persons, students. Abbreviations - CM: Chiari 
Malformation; Syr: Syringomyelia.
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extension of the census, restricted to only a few Ital-
ian regions (Piemonte and Valle d’Aosta), but with 
standardized access to the Syr and CM diagnosis and 
with availability of epidemiological data, also for Syr, 
included in the registry. More analytic and association 
analyses will need to be performed in the future. 
CONCLUSIONS
The systematization of few known facts and the dis-
semination of guidelines or, failing these, of recommen-
dations, as the result of a rational consensus by experts, 
represents a valuable tool for knowledge transfer drawn 
from biomedical and social and healthcare practices. 
We propose: adoption of Consortium Recommenda-
tions at national level to standardize the accessibility 
to the diagnosis and care process; moreover, the extend 
the methodology of census study in the national con-
text to complete Italian epidemiologic data on Chiari 
and Syr. The estimated prevalence at national level 
could have a great impact in the field of rationalization 
of diagnostic costs and reduction of unnecessary hos-
pitalizations/surgeries. We believe shared Interregional 
Table 4
Demographic, radiological and prevalence/incidence data in CS and ACM patients
Total CM (CM)
n = 347
Symptomatic-
Chiari Syndrome (CS)
n  = 139
Asymptomatic (ACM)
n = 208 
Age (%)
Pediatric (≤18 yrs) 
Adult (18-60 yrs)
Over 60 yrs
69 (20)
215 (62)
  63 (18)
20 (29)
87 (40)
32 (51)
49 (71)
128 (60)
  31 (49)
Gender (%)
Male 111 (32) 52 (47)  59 (53)
Female 236 (68) 87 (37) 149 (63)
MRI Morphology (%)
Tonsillar herniation ≥5mm 323 (93) 137 (42) 186 (58)
Tonsillar herniation 3-4mm 14 (4)   12 (17)    2 (83)
Tonsillar herniation ≤3 mm 10 (3) 0    10 (100)
Types (%)
CMI A - CMI+Syr  125 (36) 75 (60) 50 (40)
CMI B-isolated 201 (58) 50 (25) 151 (75)
CMII + Myelomeningocele a   4 (1)    4 (100)   0 (0)
Other associated conditions b 17 (5) 10 (59)    7 (41)
Prevalence c 
[x100 000] and relative 95% Confidence Intervals
7.74 (6.965-8.596) 3.10 (2.625-3.659) 4.64 (4.049-5.313)
Gender
Male 5.13 (4.260-6.177) 2.40 (1.833-3.151) 2.73 (2.114-3.517)
Female 10.17(8.952-11.55) 3.75 (3.039-4.624) 6.42 (5.469-7.537)
Age
Pediatric (≤18 yrs) 9.42 (7.441-11.951) 2.73 (1.767-4.216) 6.69 (5.058-8.839)
Adult (18-60 yrs) 8.74 (7.650-9.992) 3.54 (2.868-4.363) 5.21 (4.378-6.188)
Over 60 yrs 4.87 (3.810-6.235) 2.47 (1.754-3.495) 2.40 (1.690-3.404)
2011 Incidence d
[x100 000] and relative 95% Confidence Intervals
3.08 (2.605-3.635) 1.23 (0.942-1.596) 1.85 (1.493-2.294)
Gender
Male 2.36 (1.793-3.099) 1.25 (0.858-1.816) 1.11 (0.745-1.650)
Female 3.75 (3.039-4.624) 1.21 (0.835-1.744) 2.54 (1.971-3.279)
Age
Pediatric (≤18 yrs) 4.09 (2.868-5.844) 1.09 (0.553-2.154) 3.00 (1.983-4.546)
Adult (18-60 yrs) 3.54 (2.868-4.363) 1.47 (1.057-2.027) 2.07 (1.577-2.727)
Over 60 yrs 1.62 (1.063-2.484) 0.85 (0.475-1.524) 0.77 (0.420-1.424)
aCMII + Myelomeningocele: 75% of patients present also Syr; bOther associated conditions: 41% Retroflexed Odontoid, 24% Hydrocephalus, 24% Klippel-Feil, 11% 
TCS; cPrevalence cases/100 000 population who were alive in 2011 (ISTAT data); dNew reported cases /100 000 population who were alive in 2011 (ISTAT data).
Abbreviations - CM: Chiari Malformation; Syr: Syringomyelia; TCS: Tethered Cord Syndrome.
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Recommendations will help the promotion of national/
international clinical research, i.e. multi-center pro-
spective study to evaluate surgery efficacy in different 
clinical phenotypes (CMI with or without Syr/HDCT/
TCS).
Finally, the design and the implementation of a spe-
cific registry dedicated to Syr and CM will contribute to 
better understanding the natural history of patients af-
fected by these conditions. In fact, the European Com-
mission is supporting European Reference Networks 
for implementing new registries on RDs. The collabo-
ration and the strong linkage of activities at regional 
level with other initiatives at European level, such as 
European Reference Networks, will provide additional 
opportunities in the research and clinical aspect of Syr 
and CM.
Table 5
Demographic, radiological and Prevalence/Incidence data in Symptomatic Syr (SS) and in Asymptomatic Syr (AS) patients
Total
(Syr) 
n = 217
Symptomatic Syr 
(SS) 
n = 135
Asymptomatic
(AS)
n = 82
Age (%)
Pediatric (≤18 yrs) 
Adult (18-60 yrs)
Over 60 yrs
  24 (11)
145 (67)
  48 (22)
  9 (37)
96 (66)
30 (62)
15 (63)
49 (34)
18 (38)
Gender (%)
Male   78 (36) 50 (64) 28 (36)
Female 139 (64) 85 (61) 54 (39)
MRI Morphology (%)
Syr 158 (73) 123 (78) 35 (22)
Hydro 59 (27) 12 (20) 47 (80)
MRI Distribution (%)
Syringobulbia   2 (1)   2 (100) 0
Syr/Hydro cervical 54 (25) 33 (61) 21 (39)
Syr/Hydro thoracic 52 (24) 12 (23) 40 (77)
Syr/Hydro cervical-thoracic 109 (50) 88 (81) 21 (19)
Aetiology (%)
Type I-primary Syr 128 (59) 95 (74) 33 (26)
Type II-idiopathic Syr 20  (9) 10 (50) 10 (50)
Type III-secondary Syr  30 (14) 23 (77)   7 (23)
Type IV - pure Hydro  39 (18)   7 (18) 32 (82)
Prevalencea 
[x100 000] and relative 95% Confidence Intervals
4.84 ( 4.124-5.527) 3.01 (2.544-3.563) 1.83 (1.473-2.269)
Gender
Male 3.60 (2.889-4.499) 2.31 (1.753-3.046) 1.29 (0.895-1.870)
Female 5.99 (5.073-7.071) 3.66 (2.962-4.528) 2.33 (1.783-3.036)
Age
Pediatric (≤18 yrs) 3.28 (2.201-4.873) 1.23 (0.646-2.334) 2.05 (1.240-3.378)
Adult (18-60 yrs) 5.90 (5.012-6.937) 3.90 (3.197-4.767) 2.00 (1.507-2.634)
Over 60 yrs 3.71 (2.801-4.923) 2.32 (1.626-3.313) 1.39 (0.881-2.201)
2011 Incidenceb
[x100 000] and relative 95% Confidence Intervals
0.82 (0.599-1.137) 0.51 (0.342-0.770) 0.31 (0.186-0.5524)
Gender
Male 0.60 (0.351-1.028) 0.46 (0.251-0.851) 0.14 (0.047-0.408)
Female 1.03 (0.695-1.539) 0.56 (0.327-0.958) 0.47 (0.265-0.849)
Age
Pediatric (≤18 yrs) 0.82 (0.375-1.786) 0.14 (0.024-0.773) 0.68 (0.291-1.597)
Adult (18-60 yrs) 1.06 (0.722-1.549) 0.81 (0.526-1.256) 0.25 (0.112-0.532)
Over 60 yrs 0.39 (0.165-0.906) 0.16 (0.042-0.564) 0.23 (0.079-0.682)
a Prevalence cases/100 000 population who were alive in 2011 (ISTAT data); b New Reported cases /100 000 population who were alive in 2011 (ISTAT data); 
Abbreviations: Syr - Syringomyelia; Hydro - Hydromyelia.
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